皓天財經集團(01260.HK)年度收益約2.39億港元 同比減少約13.4%
格隆匯6月28日丨皓天財經集團(01260.HK)公吿,截至2024年3月31日止年度,集團收益約港幣2.39億元,同比減少約13.4%。集團錄得虧損約港幣6650萬元,而截至2023年3月31日止年度利潤約為港幣2720萬元。每股虧損5.78港仙。
集團的業務包括兩個主要業務分部,即財經傳訊服務分部和國際路演服務分部。公司國際路演服務包括協調、籌辦和管理路演整體後勤安排,使公司的客户能夠在路演期間專注於內容展示方面。截至2023年3月31日止年度,由於全球疫情,公司沒有進行路演。隨着中港邊境於2023年1月8日重新開放,以及全球各地解除封鎖措施,該業務分部開始恢復。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.